DAX24.856 -0,5%Est506.036 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,7200 -0,6%Nas23.066 -0,2%Bitcoin56.393 -2,5%Euro1,1869 -0,1%Öl69,63 +0,8%Gold5.060 -0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Gerresheimer A0LD6E SAP 716460 Rheinmetall 703000 BASF BASF11 NVIDIA 918422 Deutsche Telekom 555750 Lufthansa 823212 Commerzbank CBK100 Microsoft 870747 Amazon 906866 Allianz 840400 DroneShield A2DMAA Bayer BAY001 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel in Rot -- US-Börsen kaum bewegt -- Deutsche Börse mit Rekordergebnis -- Siemens Energy: Rekordaufträge -- Lufthansa, Commerzbank, BMW, Telekom, Lyft, Moderna, Robinhood im Fokus
Top News
Ausblick: CANCOM SE legt Zahlen zum jüngsten Quartal vor Ausblick: CANCOM SE legt Zahlen zum jüngsten Quartal vor
Ausblick: Mercedes-Benz veröffentlicht Zahlen zum vergangenen Quartal Ausblick: Mercedes-Benz veröffentlicht Zahlen zum vergangenen Quartal
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Noch bis 14. April bei der Commerzbank gebührenfrei in Vanguard-ETFs investieren

Eli Lilly Aktie

Kaufen
Verkaufen
Eli Lilly Aktien-Sparplan
854,30 EUR -7,70 EUR -0,89 %
BMN
1.013,87 USD -0,97 USD -0,10 %
nachbörslich
BTT
Eli Lilly jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.828,74 Mrd. EUR

KGV46,82Div. Rendite0,56%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN858560

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5324571083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
EN, Eli LillyLilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
PR NewswireLilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
EN, Eli LillyLilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
EN, Eli LillyLilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PR NewswireLilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
EN, Eli LillyAn open letter regarding access and insurance coverage for people living with obesity
EN, Eli LillyLilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
PR NewswireLilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
EN, Eli LillyZepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
PR NewswireZepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
PR NewswireLilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
EN, Eli LillyLilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
EN, Eli LillyLilly announces transitions in executive leadership
PR NewswireLilly announces transitions in executive leadership
PR NewswireLilly declares second-quarter 2025 dividend
EN, Eli LillyLilly declares second-quarter 2025 dividend
PR NewswireLilly to participate in Bank of America Securities 2025 Healthcare Conference
EN, Eli LillyLilly to participate in Bank of America Securities 2025 Healthcare Conference
EN, Eli LillyLilly reports first-quarter 2025 financial results and highlights pipeline momentum
PR NewswireLilly reports first-quarter 2025 financial results and highlights pipeline momentum
PR NewswireLilly confirms date and conference call for first-quarter 2025 financial results announcement
EN, Eli LillyLilly confirms date and conference call for first-quarter 2025 financial results announcement
EN, Eli LillyLilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
PR NewswireLilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
EN, Eli LillyStatement: Lilly has no affiliation with hims & hers
EN, Eli LillyLilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
PR NewswireLilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
EN, Eli LillyLilly’s statement about the CHMP opinion issued for donanemab
EN, Eli LillyLillyDirect platform expands to facilitate access to Alzheimer's disease care
PR NewswireLillyDirect platform expands to facilitate access to Alzheimer's disease care
EN, Eli LillyLilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
PR NewswireLilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
PR NewswireLilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
EN, Eli LillyLilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
PR NewswireLilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
EN, Eli LillyLilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
PR NewswireLilly to participate in Leerink Partners Global Healthcare Conference
EN, Eli LillyLilly to participate in Leerink Partners Global Healthcare Conference
PR NewswireLilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhi...
PR NewswireLilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.